Ganx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ganx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ganx Today - Breaking & Trending Today

Gain Therapeutics, Inc. (NASDAQ:GANX) Sees Significant Growth in Short Interest

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 149,600 shares, a growth of 8.3% from the March 31st total of 138,100 shares. Currently, 1.1% of the company’s shares are short sold. Based on an […] ....

Jeffrey Scott Riley , Gain Therapeutics Company Profile , Gain Therapeutics Inc , Gain Therapeutics , Get Free Report , Director Jeffrey Scott Riley , Gain Therapeutics Daily , Nasdaq Ganx ,

Gain Therapeutics, Inc. (NASDAQ:GANX) Director Acquires $115,800.00 in Stock

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) Director Jeffrey Scott Riley bought 30,000 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were purchased at an average price of $3.86 per share, for a total transaction of $115,800.00. Following the completion of the transaction, the director now owns 30,000 […] ....

Jeffrey Scott Riley , Royal Bank , Newedge Advisors , Renaissance Technologies , Dimensional Fund Advisors , Gain Therapeutics Inc , Securities Exchange Commission , Gain Therapeutics , Get Free Report , Director Jeffrey Scott Riley , Exchange Commission , Street Group , Fund Advisors , Chardan Capital , Gain Therapeutics Daily , Nasdaq Ganx , Insider Trading , Nsider Trades ,

Gain Therapeutics, Inc. (NASDAQ:GANX) Director Jeffrey Scott Riley Acquires 30,000 Shares

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) Director Jeffrey Scott Riley bought 30,000 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were acquired at an average cost of $3.86 per share, for a total transaction of $115,800.00. Following the purchase, the director now directly owns 30,000 shares in […] ....

Jeffrey Scott Riley , Newedge Advisors , Renaissance Technologies , Securities Exchange Commission , Susquehanna International Group , Dimensional Fund Advisors , Gain Therapeutics Company Profile , Gain Therapeutics Inc , Gain Therapeutics , Get Free Report , Director Jeffrey Scott Riley , Exchange Commission , Fund Advisors , Street Group , Edge Advisors , International Group , Chardan Capital , Gain Therapeutics Daily , Nasdaq Ganx , Insider Trading , Nsider Trades ,

Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 143,200 shares, a decline of 18.9% from the November 15th total of 176,500 shares. Based on an average daily trading volume, of 60,000 shares, the short-interest […] ....

Dimensional Fund Advisors , Geode Capital Management , Newedge Advisors , Renaissance Technologies , Blackrock Inc , Gain Therapeutics Inc , Maxim Group , Gain Therapeutics , Get Free Report , Capital Management , Fund Advisors , Site Directed Enzyme Enhancement Therapy , Gain Therapeutics Daily , Nasdaq Ganx ,

Gain Therapeutics (NASDAQ:GANX) PT Lowered to $9.00 at HC Wainwright

Gain Therapeutics (NASDAQ:GANX – Free Report) had its price objective reduced by HC Wainwright from $10.00 to $9.00 in a research report report published on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2023 earnings at ($0.33) EPS, FY2023 earnings at […] ....

Nova Scotia , Gain Therapeutics Inc , Maxim Group , Raymond James Associates , Renaissance Technologies , Geode Capital Management , Blackrock Inc , Royal Bank , Gain Therapeutics , Free Report , Get Free Report , Capital Management , Raymond James , Site Directed Enzyme Enhancement Therapy , Gain Therapeutics Daily , Nasdaq Ganx , Lower Price Target , Hc Wainwright ,